Opinion on Pharmaceuticals and Healthcare

The following industries match your search criteria:

Published within

« | 1 | » »|

Click here to sort results by relevance. Click on heading titles to sort results by different field.

Type Product title / description Pub Price
Expert View
Expert View

Advair: GlaxoSmithKline to lead the asthma market

New research from Datamonitor has suggested that the asthma/COPD market will enjoy a 35% increase and reach a value of over $18 billion by 2011. This growth will be largely driven by the success of drug delivery technology, rather than novel drug launches. GlaxoSmithKline should therefore be the main beneficiary of this market expansion although its rivals are looking to close the gap.

Published By Datamonitor
24 Oct 2003
CommentWire
CommentWire

Buffalo Grill: mad cow show

Of the four people to have contracted the human form of mad cow disease in France so far, two have died. Both were regular customers of steakhouse chain Buffalo Grill. Allegations that the chain served British beef while it was banned in France have made headlines around Europe. The case once again highlights public concern and skepticism over food safety.

Published By Datamonitor
26 Feb 2003
Expert View
Expert View

Food Allergies: Drug makers set to capitalize?

Although food allergies have been recognized in the medical community since the beginning of the century, they have recently been receiving much more public attention due to the perceived increasing prevalence of the condition in the US, Europe and Japan. As new research and treatments emerge, the potential for increased profits in this under-treated area will increase dramatically.

Published By Datamonitor
12 Sep 2003
Expert View
Expert View

Fungal Infections: Maximizing potential in a saturated market

Superficial fungal infections are found on the peripheral surfaces of the body such as the skin, hair and nails. In spite of posing no threat of mortality, these infections are very common and represent an attractive potential market. However, low presentation rates and frequent misdiagnosis mean that only a small proportion of this patient potential is currently being realized. <BR />

Published By Datamonitor
06 Jun 2003
Expert View
Expert View

Novel treatment paradigms in asthma and COPD

Asthma and chronic obstructive pulmonary disease (COPD) are chronic lung disorders affecting over 80 million people in the seven major drug markets. The prevalence of asthma has risen dramatically over the last 30 years, and due to tobacco consumption in the 1970s and 1980s, COPD has also become a major problem, costing the US health system over $30 billion in medical costs in 2000.

Published By Datamonitor
14 Jul 2003
Expert View
Expert View

Oral Mucositis: Amgen's Palifermin a potential treatment

Oral mucositis is a common and debilitating side effect of cancer therapies that threatens the successful treatment of 600,000 people worldwide. Inexpensive treatments can sometimes alleviate mucositis, but a truly effective treatment has yet to be launched. With Palifermin already in phase III trials, Amgen is already planning on filling this void. This outcome however, is less than certain.

Published By Datamonitor
19 Sep 2003
Expert View
Expert View

Using the Internet: Can Pharmaceutical companies afford to ignore the Net?

The considerable investment and overheads required for the development of new drugs mean that pharmaceutical companies must establish brand loyalty throughout a product's lifecycle in order to protect sales at patent expiry. While marketing has always been key to this, the advent of the Internet has meant that there are now a whole host of new opportunities for influencing market trends.<BR />

Published By Datamonitor
04 Apr 2003

« | 1 | » »|

No help is available.